VanEck Pharmaceutical ETF (NASDAQ:PPH) Hits New 1-Year High at $93.50

VanEck Pharmaceutical ETF (NASDAQ:PPH) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $93.50 and last traded at $93.50, with a volume of 6127 shares traded. The stock had previously closed at $92.82.

VanEck Pharmaceutical ETF Stock Up 1.0 %

The company’s 50-day moving average price is $90.87 and its 200-day moving average price is $88.35. The firm has a market cap of $631.81 million, a price-to-earnings ratio of 21.04 and a beta of 0.72.

VanEck Pharmaceutical ETF Cuts Dividend

The company also recently announced a dividend, which was paid on Friday, July 5th. Investors of record on Monday, July 1st were paid a dividend of $0.3558 per share. The ex-dividend date was Monday, July 1st.

Hedge Funds Weigh In On VanEck Pharmaceutical ETF

Hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP purchased a new position in shares of VanEck Pharmaceutical ETF during the fourth quarter worth approximately $28,000. Global Retirement Partners LLC lifted its holdings in shares of VanEck Pharmaceutical ETF by 2,343.8% during the first quarter. Global Retirement Partners LLC now owns 391 shares of the company’s stock worth $35,000 after purchasing an additional 375 shares during the period. CWM LLC acquired a new stake in shares of VanEck Pharmaceutical ETF during the second quarter worth $55,000. CoreFirst Bank & Trust acquired a new stake in shares of VanEck Pharmaceutical ETF during the third quarter worth $76,000. Finally, Comerica Bank lifted its holdings in shares of VanEck Pharmaceutical ETF by 39.4% during the first quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after purchasing an additional 378 shares during the period.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.